Vera Therapeutics, INC 8-K filings

Vera Therapeutics has appointed Nancy Bowman as Chief Regulatory Officer, succeeding William Turner who will transition to a Special Advisor role.

Vera Therapeutics announced FDA accelerated approval for TRUTAKNA to treat primary IgA nephropathy.

Vera Therapeutics announced an updated plan with the FDA for atacicept's IgA Nephropathy approval, expecting eGFR results in Q3 2026 and a supplemental BLA submission in Q4 2026.

Vera Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Vera Therapeutics announced Q1 2026 financial results, highlighting the FDA's Priority Review for atacicept in IgAN with a July 7, 2026 PDUFA date, and providing updates on corporate progress and upcoming milestones.

Vera Therapeutics announced positive Phase 3 data for atacicept in IgA nephropathy, received FDA priority review, and reported full year 2025 financial results including a net loss of $299.6 million.

Vera Therapeutics, Inc. announced that Jason Carter will depart from his role as Chief Legal Officer, effective December 24, 2025.

Vera Therapeutics, Inc. announced the pricing and full exercise of an option for its follow-on public offering, raising approximately $300 million in gross proceeds.

Vera Therapeutics, Inc. announced the appointment of James R. Meyers to its Board of Directors, effective November 25, 2025, who will also serve on the Audit Committee.

Vera Therapeutics announced positive Phase 3 ORIGIN trial results for atacicept in IgA nephropathy, showing significant proteinuria reduction and a favorable safety profile.

Vera Therapeutics announced its third-quarter 2025 financial results and provided key updates on its atacicept clinical program, including an anticipated BLA submission for IgAN in Q4 2025.

Vera Therapeutics, Inc. has established a new 'at-the-market' equity offering program, allowing it to sell up to $200 million of its Class A common stock.

Vera Therapeutics announced positive Phase 3 trial results for atacicept in IgA Nephropathy, paving the way for a Q4 2025 FDA submission and potential 2026 commercial launch.

Vera Therapeutics, Inc. has entered into a Loan and Security Agreement for up to $500 million in term loans, providing significant capital to advance its clinical programs and support potential commercialization, with tranches tied to key development and revenue milestones.

Vera Therapeutics announced positive 36-week results from its ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgA nephropathy (IgAN), demonstrating a statistically significant reduction in proteinuria and a favorable safety profile, with plans for accelerated FDA approval submission in Q4 2025.

Vera Therapeutics held its 2025 Annual Meeting of Stockholders on May 14, 2025, with stockholders voting on the election of directors, ratification of the independent accounting firm, and executive compensation.

Vera Therapeutics reports Q1 2025 financial results and remains on track to announce pivotal Phase 3 trial results for atacicept in IgAN, with potential FDA submission planned for Q4 2025.

Vera Therapeutics is on track to announce Phase 3 trial results for its IgAN treatment and plans for FDA submission in 2025, supported by a strengthened balance sheet.

Vera Therapeutics presented an update on its clinical programs, including the Phase 3 trial for atacicept in IgAN, at the J.P. Morgan Healthcare Conference.

Vera Therapeutics reported positive 96-week data from its atacicept trial, completed a $345 million equity offering, and is on track for Phase 3 topline results in Q2 2025.

Vera Therapeutics has entered into an underwriting agreement for a public offering of 7,142,858 shares of its Class A common stock, expected to generate gross proceeds of approximately $300 million.

Vera Therapeutics reported positive 96-week data from its Phase 2b ORIGIN trial of atacicept in IgAN, showing sustained reductions in key disease markers and stabilization of kidney function.

Vera Therapeutics announces the expansion of its atacicept development program into multiple autoimmune kidney diseases with the initiation of two new studies, ORIGIN Extend and PIONEER.

Vera Therapeutics announced FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy and reported its second quarter 2024 financial results.

Vera Therapeutics has announced the appointment of David Johnson as its new Chief Operating Officer, effective July 1, 2024.

Vera Therapeutics has appointed Christy Oliger to its Board of Directors, effective immediately, and granted her stock options and restricted stock units.

Vera Therapeutics held its 2024 Annual Meeting of Stockholders, electing three Class III directors and ratifying KPMG LLP as its independent auditor for the fiscal year ending December 31, 2024.

Vera Therapeutics announced positive 72-week data from its Phase 2b ORIGIN trial for IgAN, completed a $287.5 million financing, and provided updates on its clinical programs.

Vera Therapeutics announced positive 72-week data from its Phase 2b trial for atacicept in IgAN, along with a $287.5 million financing to support its clinical programs.

Vera Therapeutics has entered into an underwriting agreement for a public offering of 8,064,517 shares of its Class A common stock, expected to generate gross proceeds of approximately $250 million.